Controlled Release Drug Delivery Market Size & Share, by Product Type (Metered Dose Inhalers, Injectables, Infusion Pumps, Drug Eluting Stents, Nasal Spray); Technology Type (Wurster Technique, Implants, Micro Encapsulation, Targeted Delivery); Application Type (Oral, Nasal, Topical, Implantable, Injectable Targeted Delivery); Release Mechanism and By End User - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Growth Drivers

• Rise in the Population Globally: There is a significant rise in the population of old people and children. Most of the old population suffers from health related problems, such as, compromised physical and mental functions that affect the intake of their medications. In addition, the body of the children and old people cannot tolerate the side effects of the drugs and its high dosage. Hence, with rising population of patients and its various innovations, the controlled release drug delivery market will witness a steep growth during the forecast period
• Advancements in the Drug Delivery Systems: The factor driving the controlled release drug delivery market is the rise in the spending of research & development to cure the non communicable diseases and diseases persisting for a long time, efficiently.  The systems are working to be mechanically strong in order to stabilize the medical condition of the patient along with the achievement of high drug loading. Moreover, the research and development is working on cost effective controlled release drug delivery technology, which is estimated to increase the notable rate of its adoption over the forecast period.

Challenges

• High Cost of Controlled Release Drug Delivery Technology and Non-Biocompatibility of Materials Used: Despite of the advantages related to the controlled release drug delivery technology, high cost of the system and non biocompatibility & biodegradability with appropriate controlled release properties of the material used in drugs is expected to act as a key restraint to the growth of controlled release drug delivery market. Further, the inactive substances that act as a medium for a drug are deemed acceptable for the therapy of children are very few and the need for high dose of API (Active Pharmaceutical Ingredient) is hampering the growth of the controlled release drug delivery market.